Abstract Objectives In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI)
dolutegravir was recently introduced for the treatment of HIV-1 infection. Since pretreatment …

Background Transition to dolutegravir-based regimens in resource-limited settings (RLS)
requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore …

Objectives To investigate the prevalence and patterns of major and accessory resistance
mutations associated with integrase strand transfer inhibitors (INSTIs), across diverse HIV-1 …

Abstract Introduction Sub-Saharan African countries are introducing integrase strand
transfer inhibitors (INSTIs) in their ART programmes as the preferred first-line regimen, and …

Background: Integrase strand-transfer inhibitor (INSTI)-containing regimens have gradually
been administered in Guangdong Province, China beginning in 2016, and INSTI-related …

Objective: Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy
(ART). However, prevalence data on natural resistance to integrase inhibitors [integrase …

The growing emergence of non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV drug
resistance in sub-Saharan Africa (SSA) led to the World Health Organization (WHO) …

Background Despite the scale-up of ART and the rollout in Tanzania of dolutegravir, an
integrase strand transfer inhibitor (INSTI), treatment success has not been fully realized. HIV …

Objectives The objective of this study was to define the natural genotypic variation of the HIV-
1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer …

Background and Objective: Integrase strand transfer inhibitors (INSTIs) are currently the
standard of practice for first-line HIV therapy for most patients. We evaluated the mutations …